Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferenc Nagy

Showing results (241-250 of 252) with videos related to

Pageof 26
Sort By:
Orvosi Hetilap|August 26, 2011
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary]Lajos Sándor Kiss, Tamás Szamosi, Tamás Molnár, et al.
BMC Neurology|September 19, 2021
The role of hybrid FDG-PET/MRI on decision-making in presurgical evaluation of drug-resistant epilepsyMárton Tóth, Péter Barsi, Zoltán Tóth, et al.
Journal of Crohn'S & Colitis|December 15, 2015
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide CohortKrisztina B Gecse, Barbara D Lovász, Klaudia Farkas, et al.
Journal of Medical Systems|August 21, 2022
Multicenter Study on COVID-19 Lung Computed Tomography Segmentation with varying Glass Ground Opacities using Unseen Deep Learning Artificial Intelligence Paradigms: COVLIAS 1.0 ValidationJasjit S Suri, Sushant Agarwal, Luca Saba, et al.
F1000Research|June 11, 2025
Healing through faith: Meeting a chaplain coupled with biblical readings could produce lymphocyte changes that correlate with brain activity (HEALING study)András Béres, Miklós Emri, Csaba Aranyi, et al.
Inflammatory Bowel Diseases|September 19, 2017
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide CohortLorant Gonczi, Krisztina B Gecse, Zsuzsanna Vegh, et al.
BMC Gastroenterology|September 11, 2009
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational studyPál Miheller, Péter L Lakatos, Gábor Horváth, et al.
Expert Opinion on Drug Safety|May 16, 2017
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohortAnita Bálint, Mariann Rutka, Zsuzsanna Végh, et al.
Plant, Cell & Environment|June 17, 2024
A synchronized, large-scale field experiment using Arabidopsis thaliana reveals the significance of the UV-B photoreceptor UVR8 under natural conditionsSusanne Neugart, Viktoria Steininger, Catarina Fernandes, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
COVLIAS 1.0<sub>Lesion</sub> vs. MedSeg: An Artificial Intelligence Framework for Automated Lesion Segmentation in COVID-19 Lung Computed Tomography ScansJasjit S Suri, Sushant Agarwal, Gian Luca Chabert, et al.
Pageof 26

Showing results (241-250 of 252) with videos related to

Sort By:
Pageof 26
Orvosi Hetilap|August 26, 2011
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary]Lajos Sándor Kiss, Tamás Szamosi, Tamás Molnár, et al.
BMC Neurology|September 19, 2021
The role of hybrid FDG-PET/MRI on decision-making in presurgical evaluation of drug-resistant epilepsyMárton Tóth, Péter Barsi, Zoltán Tóth, et al.
Journal of Crohn'S & Colitis|December 15, 2015
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide CohortKrisztina B Gecse, Barbara D Lovász, Klaudia Farkas, et al.
Journal of Medical Systems|August 21, 2022
Multicenter Study on COVID-19 Lung Computed Tomography Segmentation with varying Glass Ground Opacities using Unseen Deep Learning Artificial Intelligence Paradigms: COVLIAS 1.0 ValidationJasjit S Suri, Sushant Agarwal, Luca Saba, et al.
F1000Research|June 11, 2025
Healing through faith: Meeting a chaplain coupled with biblical readings could produce lymphocyte changes that correlate with brain activity (HEALING study)András Béres, Miklós Emri, Csaba Aranyi, et al.
Inflammatory Bowel Diseases|September 19, 2017
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide CohortLorant Gonczi, Krisztina B Gecse, Zsuzsanna Vegh, et al.
BMC Gastroenterology|September 11, 2009
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational studyPál Miheller, Péter L Lakatos, Gábor Horváth, et al.
Expert Opinion on Drug Safety|May 16, 2017
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohortAnita Bálint, Mariann Rutka, Zsuzsanna Végh, et al.
Plant, Cell & Environment|June 17, 2024
A synchronized, large-scale field experiment using Arabidopsis thaliana reveals the significance of the UV-B photoreceptor UVR8 under natural conditionsSusanne Neugart, Viktoria Steininger, Catarina Fernandes, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
COVLIAS 1.0<sub>Lesion</sub> vs. MedSeg: An Artificial Intelligence Framework for Automated Lesion Segmentation in COVID-19 Lung Computed Tomography ScansJasjit S Suri, Sushant Agarwal, Gian Luca Chabert, et al.
Pageof 26